Modulation of Pulmonary Inflammation and the Redox Pathway In Vitro and In Vivo by Fumaric Ester.

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Toxicology

Background:

• Chronic obstructive pulmonary disease (COPD) involves chronic lung inflammation and emphysema, with current treatments offering only symptomatic relief.
• Antioxidant and anti-inflammatory agents, like dimethyl fumarate (DMF), are being investigated for their therapeutic potential in COPD management.

Purpose of the Study:

• To evaluate the efficacy of dimethyl fumarate (DMF) and its metabolite, monomethyl fumarate (MMF), in mitigating pulmonary inflammation and oxidative stress.
• To assess the protective effects of DMF against cigarette smoke extract (CSE)-induced inflammation in vitro and porcine pancreatic elastase (PPE)-induced emphysema in vivo.

Main Methods:

• In vitro: Human pulmonary epithelial cells (PC-9) were treated with MMF and exposed to CSE to measure cell viability, oxidative stress (ROS), lipid peroxidation, and nitrite production.
• In vivo: C57BL/6 mice received DMF treatment during and after PPE-induced emphysema induction. Analyses included ROS levels, bronchoalveolar lavage fluid (BALF) cell counts, lung histology, and oxidative stress protein expression (SOD1, HO-1).

Main Results:

• MMF demonstrated significant reduction in oxidative stress and lipid peroxidation in vitro.
• In vivo, DMF treatment decreased ROS levels, reduced pulmonary inflammation, and prevented lung tissue damage, including alveolar enlargement.
• DMF modulated the expression of key oxidative stress proteins, SOD1 and HO-1.

Conclusions:

• Dimethyl fumarate (DMF) exhibits significant anti-inflammatory and antioxidant effects in preclinical models of COPD.
• DMF demonstrates potential as an effective therapeutic strategy for COPD by targeting underlying oxidative stress and inflammation.
• Further investigation into DMF as a novel therapeutic agent for COPD is warranted.